GenSight Biologics raises EUR 1 million in private placement backed by Heights Capital, Invus
PUBT · 2d ago
Share
Listen to the news
- GenSight Biologics priced a € 1 million private placement backed by existing shareholders Heights Capital and Invus.
- Structure combines 2,597,404 new shares, 11,940,300 pre-funded warrants, and 14,537,704 investor warrants.
- Gross proceeds € 1 million; net proceeds about € 950,000.
- Funds earmarked for operations and working capital pending structural financing for the Phase III RECOVER trial.
- New shares priced at € 0.077 per ABSA; pre-funded unit priced at € 0.067; investor warrant exercise price € 0.0497.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gensight Biologics SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20261007598026) on October 08, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending